Tesaro misses by $0.30, beats on revs (124.31 -2.99)
- Reports Q2 (Jun) loss of $2.82 per share, $0.30 worse than the Capital IQ Consensus of ($2.52); revenues fell 17.6% year/year to $29.5 mln vs the $18.61 mln Capital IQ Consensus.
- Upcoming Milestones: ZEJULA (niraparib): Continue to execute on the ongoing U.S. launch of ZEJULA and solidify its position as the market leading PARP inhibitor for patients with recurrent ovarian cancer. Launch ZEJULA in Europe by year-end 2017, pending European Commission approval. Continue to enroll the Phase 3 PRIMA trial throughout 2017. Begin to initiate expanded ovarian, breast and lung cancer development programs in 2017